Literature DB >> 21056887

Increased postabsorptive and exercise-induced whole-body glucose production in patients with chronic obstructive pulmonary disease.

Frits M E Franssen1, Hans P Sauerwein, Mariette T Ackermans, Erica P A Rutten, Emiel F M Wouters, Annemie M W J Schols.   

Abstract

Skeletal muscle biopsy studies have consistently shown a decreased oxidative phenotype in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Limited information is available regarding potential adaptations or abnormalities in anaerobic metabolism and glucose homeostasis. Whole-body glucose production was assessed at rest and during exercise in COPD patients with moderate disease severity (forced expiratory volume in 1 second, 52% ± 3%), prestratified into normal-weight (n = 7; body mass index [BMI], 27.5 ± 0.9 kg·m(-2)) and underweight subjects (n = 6; BMI, 20.6 ± 0.7 kg·m(-2)), and in 8 healthy controls matched for age and BMI with the normal-weight COPD group. Glucose tolerance was normal in all subjects. Rate of appearance (R(a)) of glucose at rest and during submaximal cycling exercise was measured in postabsorptive state by infusion of stable isotope tracer [6,6-(2)H(2)]glucose. Resting glucose R(a) was significantly enhanced in underweight COPD patients compared with controls (16.7 ± 0.3 vs 15.1 ± 0.4 μmol·kg fat-free mass(-1)·min(-1), P < .05) and was inversely related to fat-free mass (r = -0.75, P < .01). Furthermore, the exercise-induced increase in glucose R(a) was enhanced in COPD patients (81.9% ± 3.4% vs 72.1% ± 2.0%, P = .05), resulting in elevated end-of-exercise glucose output. Differences were most pronounced in underweight patients, who were also characterized by enhanced plasma catecholamine levels and decreased insulin concentrations (all, P < .05). In normal-weight patients, there was evidence for decreased insulin sensitivity assessed by homeostatic modeling technique. Whole-body glucose production is increased in underweight COPD patients with normal glucose tolerance. It is hypothesized that lowered body weight in COPD has unique effects on glucose uptake despite reduced skeletal muscle oxidative capacity, relative hypoxemia, and sympathetic activation.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056887     DOI: 10.1016/j.metabol.2010.09.004

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease.

Authors:  Christina C Kao; Jean W-C Hsu; Venkata Bandi; Nicola A Hanania; Farrah Kheradmand; Farook Jahoor
Journal:  J Appl Physiol (1985)       Date:  2011-10-20

Review 2.  Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings.

Authors:  Joaquim Gea; Sergi Pascual; Carme Casadevall; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

3.  Casein protein results in higher prandial and exercise induced whole body protein anabolism than whey protein in chronic obstructive pulmonary disease.

Authors:  Mariëlle P K J Engelen; Erica P A Rutten; Carmen L N De Castro; Emiel F M Wouters; Annemie M W J Schols; Nicolaas E P Deutz
Journal:  Metabolism       Date:  2012-04-17       Impact factor: 8.694

4.  The brain's supply and demand in obesity.

Authors:  Britta Kubera; Christian Hubold; Sophia Zug; Hannah Wischnath; Ines Wilhelm; Manfred Hallschmid; Sonja Entringer; Dirk Langemann; Achim Peters
Journal:  Front Neuroenergetics       Date:  2012-03-08

5.  Distinct skeletal muscle molecular responses to pulmonary rehabilitation in chronic obstructive pulmonary disease: a cluster analysis.

Authors:  Anita E M Kneppers; Roy A M Haast; Ramon C J Langen; Lex B Verdijk; Pieter A Leermakers; Harry R Gosker; Luc J C van Loon; Mitja Lainscak; Annemie M W J Schols
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-01-18       Impact factor: 12.910

6.  Brown adipose tissue activation is not related to hypermetabolism in emphysematous chronic obstructive pulmonary disease patients.

Authors:  Karin J C Sanders; Roel Wierts; Wouter D van Marken Lichtenbelt; Judith de Vos-Geelen; Guy Plasqui; Marco C J M Kelders; Vera B Schrauwen-Hinderling; Jan Bucerius; Anne-Marie C Dingemans; Felix M Mottaghy; Annemie M W J Schols
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-15       Impact factor: 12.910

7.  Mapping the global research landscape and hotspot of exercise therapy and chronic obstructive pulmonary disease: A bibliometric study based on the web of science database from 2011 to 2020.

Authors:  Yu Zhou; Xiaodan Liu; Weibing Wu
Journal:  Front Physiol       Date:  2022-08-11       Impact factor: 4.755

Review 8.  Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective.

Authors:  Karin J C Sanders; Anita E M Kneppers; Coby van de Bool; Ramon C J Langen; Annemie M W J Schols
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-09-07       Impact factor: 12.910

9.  Metabolomic profiling in a Hedgehog Interacting Protein (Hhip) murine model of chronic obstructive pulmonary disease.

Authors:  Emily S Wan; Yan Li; Taotao Lao; Weiliang Qiu; Zhiqiang Jiang; John D Mancini; Caroline A Owen; Clary Clish; Dawn L DeMeo; Edwin K Silverman; Xiaobo Zhou
Journal:  Sci Rep       Date:  2017-05-31       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.